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Abstract
Escherichia coli is one of the major pathogens responsible for bactaeremia. Empirical antibiotherapy of these infections usually relies on
third-generation cephalosporins (3GCs). Thus, the occurrence and epidemiology of 3GC-resistant strains have to be monitored. The
French prospective multicentre study COLIBAFI collected 1081 strains of E. coli responsible for bacteraemia in 2005. In the present
work, the prevalence of resistance to 3GCs was evaluated, and the implicated molecular mechanisms were characterized by speciﬁc
PCR and sequencing. Phylogenetic grouping, O-typing, pulsed-ﬁeld gel electrophoresis and virulence factor analysis were used to investi-
gate the genetic background of the 3GC-resistant (3GC-R) strains. Clinical features of the patients with documented data (n = 1051)
were analysed. Decreased susceptibility to 3GCs was observed in 41 strains (3.8%): 19, 18 and four had extended-spectrum b-lactamase
(ESBL), AmpC cephalosporinase and OXA-type penicillinase phenotypes, respectively. Pulsed-ﬁeld gel electrophoresis revealed that the
3GC-R strains constitute a diverse population. All but one of the strains with an ESBL phenotype produced a CTX-M-type enzyme, and
six of them belonged to the widespread intercontinental clone O25b:H4-ST131. AmpC phenotype strains harboured various chromo-
somal ampC promoter and coding region mutations and/or the blaCMY-2 plasmidic gene. 3GC-R strains carried fewer virulence factors
and were more co-resistant to other antibiotics than 3GC-susceptible (3GC-S) strains. Infections with 3GC-R strains were mostly
community-acquired and, as compared with those caused by their 3GC-S counterparts, were more severe. Underlying chronic disease
and prior use of antibiotics were independent risk factors for development of a 3GC-R strain bacteraemia. The fact that the molecular
support of 3GC resistance is mainly plasmid-mediated represents a potentially epidemic threat.
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Introduction
Bacteraemias represent a major cause of death in industrial-
ized countries such as Europe and the USA, with large
increases in incidence and mortality being seen over the past
20 years [1]. For Escherichia coli, a leading pathogen impli-
cated in these infections [2], an increase in the prevalence
of b-lactam resistance, especially concerning the third-
generation cephalosporins (3GCs), has been observed
recently, according to the annual report of the European
Antimicrobial Resistance Surveillance System (http://www.
rivm.nl/earss). Three kinds of b-lactamase are commonly
responsible for 3GC resistance: extended-spectrum b-
lactamases (ESBLs), OXA-type penicillinases (or oxacillinases)
and AmpC cephalosporinases (chromosomal or plasmid-
mediated). Among ESBLs, the CTX-M b-lactamases have
now become most prevalent [3,4].
ª2010 The Authors
Clinical Microbiology and Infection ª2010 European Society of Clinical Microbiology and Infectious Diseases
ORIGINAL ARTICLE BACTERIOLOGY
As 3GCs form part of empirical antimicrobial chemother-
apy in severe infections, the prevalence of resistance in E. coli
is important to evaluate because of the risk of treatment fail-
ure. In 2005, a large, prospective multicentre study, COLIB-
AFI (http://www.colibaﬁ.net), was conducted to identify the
factors of severity associated with E. coli bacteraemia. The
present ancillary study aimed to investigate the prevalence
and molecular epidemiology of resistance to 3GCs of the
COLIBAFI collection, and to analyse clinical features of
patients infected by these resistant strains.
Materials and Methods
Study protocol and bacterial strains
The prospective multicentre study COLIBAFI was conducted
in 15 hospitals in different areas in France: Paris (eight hos-
pitals), Angers, Brest, Caen, Dijon, Nantes, Rennes and
Tours. All except one were university hospitals. During the
year 2005, all cases of E. coli bacteraemia, deﬁned on the
basis of the isolation of E. coli from one or more sets of
blood culture bottles, were collected by the local bacteriol-
ogy laboratory. Only patients receiving vasopressors before
the bacteraemia or patients already included in the study for
a previous episode were not considered for inclusion. Over-
all, 1099 adults were included. Forty-eight patients were
excluded either because the E. coli isolate was not available
(n = 18) or because clinical data were lacking (n = 30). Thus,
the microbiological study was conducted on 1081 strains,
and the clinical study concerned 1051 patients. Bacterial
identiﬁcation was performed with the API20E system (bio-
Merieux, Marcy l’Etoile, France). Antimicrobial susceptibility
was determined by the disk diffusion method on Mueller–
Hinton agar, and interpreted according to the 2005 guide-
lines of the Antibiogram Committee of the French Society
for Microbiology (CA-SFM) (http://www.sfm.asso.fr). The
strains were sent to a central laboratory (INSERM U722)
with clinical features of the patients and antimicrobial sus-
ceptibility data. Clinical characteristics, collected by a tandem
of senior investigators (an infectious disease clinician and
a bacteriologist) included age, sex, underlying chronic
disease, immunosuppression, antibiotherapy received within
2 weeks before the bacteraemia, community-acquired or
nosocomial infection, portal of entry and clinical outcome.
Bacteraemia episodes were deﬁned as community-acquired
if the ﬁrst positive blood culture was obtained <48 h
following hospital admission. The full description of the
cohort will be published elsewhere (A. Lefort, X. Panhard,
O. Clermont, P. L. Woerther, C. Branger, F. Mentre´,
B. Fantin, M. Wolff, E. Denamur and the COLIBAFI group;
personal communication). Strains with decreased susceptibil-
ity to cefotaxime and/or ceftazidime according to the 2005
guidelines of the CA-SFM were selected. Strains with
decreased susceptibility to cefoxitin were also considered,
as this can be a helpful marker with which to detect AmpC
production [5].
Antimicrobial susceptibility testing of the selected strains
All selected strains were tested for ESBL production by the
double-disk synergy test [6]. For the strains with a negative
test result, MICs of cefoxitin, cefotaxime, ceftazidime and
cefepime were determined by the Etest diffusion method
(AB Biodisk, Solna, Sweden).
Molecular characterization of b-lactamases
For strains with a positive double-disk synergy test result,
characterization of ESBLs was performed by speciﬁc PCR
ampliﬁcation and sequencing [7].
For strains with a negative double-disk synergy test result,
the chromosomal ampC gene, its promoter and its attenua-
tor were ampliﬁed and sequenced with primers Int-B2 and
Int-HN [8]. Mutations were studied by comparison with the
published ampC gene sequence of E. coli K-12 (GenBank
accession number NC_000913). Plasmid-mediated AmpC
cephalosporinase was detected with a multiplex PCR method
[9] and identiﬁed by sequencing.
The strains were also screened for the presence of an
OXA-type b-lactamase by PCR [10], and this was followed
by sequencing to identify the blaOXA gene.
Strain genetic background analysis
Phylogenetic grouping of the E. coli strains was determined
by a PCR-based method [11]. The strains were screened for
17 genes encoding putative virulence factors (sfa/foc, iroN,
iutA, iha, papC, papG (II and III alleles), hlyC, cnf1, hra, sat, ire,
usp, chromosomal ompT, ibeA, fyuA, irp2 and traT) by PCR
[12]. For each strain, a virulence score was deﬁned as the
sum of virulence factors present over the 17 tested. Twenty-
ﬁve O-types were determined with a molecular approach
based on allele-speciﬁc PCR [13] in the 3GC-resistant (3GC-
R) strains (see Table S1 for a list of the primers used). They
include the O-types most frequently found in extra-intestinal
pathogenic [13] and ESBL-producing [14,15] strains. An
allele-speciﬁc PCR of the pabB gene was used to detect
strains belonging to the O25b:H4-ST131 clone [16]. Pulsed-
ﬁeld gel electrophoresis was performed with a CHEF DRII
System (BioRad, Marnes-la-Coquette, France) using genomic
DNA digested with XbaI [17]. A dendrogram was
constructed using the Dice similarity coefﬁcient, and the
UPGMA algorithm was used to cluster the strains.
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Statistical analysis
The 1081 strains were considered for analysis concerning
microbiological data. Resistance to other antibiotics, phyloge-
netic group and virulence factor score were compared
between 3GC-R strains (n = 41) and the 3-GC-susceptible
(3GC-S) strains (n = 1040). A second comparison was per-
formed between the ESBL-producing strains (n = 19) and the
AmpC phenotype-expressing strains (n = 18). The clinical
characteristics of 1051 patients were studied with the avail-
able data. As above, two comparisons were made.
Comparisons of discrete variables were performed with
Fisher’s exact test, and comparisons of continuous variables
were performed using Wilcoxon–Mann–Whitney tests. All
tests were two-sided, with a type I error of 0.05. Risk
factors for 3GC resistance were also studied by backward
multivariate logistic regression. The statistical analysis was per-
formed using SAS software version 9.1.
Results and Discussion
Overall, 41 of 1081 strains (3.8% (95% CI 2.7–5.1%)) showed
decreased susceptibility to at least one of the 3GCs. This
rate is close to the percentage of 3% described for bacterae-
mias in France in 2005 by the surveillance network ONERBA
(http://www.onerba.org). Thus, because of the large number
of strains included and the participation of several hospitals
in different areas, the COLIBAFI study seems to be repre-
sentative of the situation regarding antimicrobial resistance
of E. coli in France.
ESBLs and AmpC, both equally represented, are the main
causes of resistance to 3GCs
Strains with an ESBL phenotype. The double-disk synergy test
detected 19 ESBL-producing E. coli strains, 18 of which
belonged to the CTX-M group and only one to the TEM
family (TEM-52) (Table 1). This result shows that the great
majority of ESBL-producing E. coli strains responsible for bac-
teraemia carry a blaCTX-M gene, conﬁrming the observation
of the worldwide dissemination of this type of ESBL since
the 2000s [3], both in the hospital environment and in the
community [4,18], with E. coli as a major host. To date, few
observations have been made on the prevalence of this
mechanism of resistance in such serious infections. In Spain,
two recent studies, conducted between October 2004 and
January 2006, concerning community-onset and nosocomial
bacteraemia caused by EBSL-producing E. coli, found preva-
lences of CTX-M enzymes of, respectively, 87% and 81%; the
enzymes were predominantly of the CTX-M-14 type [19,20].
However, they noted the increasing prevalence of the
CTX-M-15 type, in relation to the worldwide spread of
the ST131 clone. In the COLIBAFI study, two enzymes were
predominant: CTX-M-15 (50%) and CTX-M-14 (30%).
Strains with an AmpC phenotype. Eighteen strains had reduced
susceptibility to cefoxitin (MIC >32 mg/L) and to at least one
of the 3GCs tested, but produced no ESBL or OXA-type
penicillinase. This phenotype was compatible with the over-
production of the chromosomal AmpC enzyme resulting
from mutations in the ampC gene and/or acquisition of a
plasmid-mediated AmpC.
Plasmid-mediated AmpCs, all of the CMY-2 type, were
detected in ﬁve strains (28%). The predominance of this type
of enzyme has been described in Europe [21,22] and in
North America [5,23].
The promoter region of the ampC gene of these strains
was investigated. In 11 strains, an association of ﬁve muta-
tions (in positions )88, )82, )42, )18 and )1) was found
(Table 2). The –42 (C ﬁ T) transition is known to increase
the strength of the promoter by creating a new perfect con-
sensus sequence, TTTACA, separated by 17 bp from a new
–10 sequence created by the –18 (G ﬁ A) transition [24].
Strains lacking this pattern displayed other mutations known
to enhance the strength of the promoter: the transversion –
32 (T ﬁ A) in the –35 box [24], or single-nucleotide inser-
tions between the –35 box and the –10 box. Only two
strains (08–152 and 10–020) had a promoter region strictly
identical to that of E. coli K-12, but they both harboured a
plasmid-mediated AmpC. Finally, four strains with an MIC
for cefepime ‡4 mg/L had additional mutations in the attenu-
ator region (in position +20 or +23) (Table 2), which might
increase transcription [25]. All of these ﬁndings are consis-
tent with a recent description of the importance of these
mutations in the promoter region of the ampC gene [22].
The extension of the hydrolysis spectrum of AmpC to cefe-
pime has been related to modiﬁcations in several speciﬁc loca-
tions of the protein, and especially the H-9 helix and the H-10
helix [8,26–28]. Indeed, in our study, ﬁve strains with cefepime
MICs >1 mg/L had amino acid substitutions in these regions
(Table 2). The S287N substitution might have a greater impact
than the S287C substitution on the increase in the catalytic
efﬁciency of AmpC towards 3GCs [8], and speciﬁcally in E. coli
strains belonging to phylogroup A [28], as observed in our
study (Tables 1 and 2). The L293P substitution found in strain
08-121 (cefepime MIC of 16 mg/L) has never been described
to date in a clinical isolate of E. coli. However, it has already
been found in an in vitro mutant of the Enterobacter cloacae P99
reference strain (cefepime MIC of 8 mg/L) [26] and in a clinical
isolate of Enterobacter aerogenes (cefepime MIC of 32 mg/L)
selected during cefepime treatment [29].
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Strains with an OXA phenotype. Four strains with decreased
susceptibility to cefoxitin and showing selective hydrolysis of
cefepime produced an OXA-type penicillinase encoded by a
blaOXA-1 gene (Table 1). This gene was also found in strains
producing a CTX-M enzyme. Indeed, the blaOXA-1 gene can
be found alone or with the blaCTX-M-15 gene on the same
plasmid [3,30,31].
3GC-R strains constitute a diverse population that is more
co-resistant and has fewer virulence factors than 3GC-S
strains
Pulsed-ﬁeld gel electrophoresis revealed that the 3GC-R
strains constitute a diverse population. Six CTX-M-producing
strains, of phylogroup B2, were found in a cluster distant
from the others (Fig. 1), and belonged to the recently
described widespread intercontinental clone O25b:H4-ST131
[14,16,32]. This clone usually includes strains harbouring the
blaCTX-M15 gene, but recent studies have shown that other
types of ESBL can be found [16,31].
The 3GC-R strains had heterogeneous co-resistance
proﬁle (Tables 1 and 3). They were signiﬁcantly more
resistant than 3GC-S strains to several major antibiotics:
ciproﬂoxacin (p <0.0001), gentamicin (p <0.0001), amikacin
(p 0.01), and co-trimoxazole (p <0.0001). Ciproﬂoxacin
resistance was found in 28 of 41 strains, with a signiﬁcant
predominance in the ESBL group vs. the AmpC group
(p 0.04). Gentamicin resistance was found in ten of 41
strains: six were CTX-M-15 producers. Co-trimoxazole
was inactive in 75.6% of the cases with no difference
between ESBL– and AmpC–producing strains. All of
these ﬁndings concerning multiresistance in ESBL-
producing E. coli strains highlight the difﬁculty in ﬁnding an
TABLE 1. Characteristics of the Escherichia coli isolates resistant to third-generation cephalosporins
Strain ID
b-Lactam
resistance type Phylogroupa O-typeb VF scorec Co-resistanced
02-007 CTX-M-9 B2 5 S, K, G, T, N, A, Te, Mi, Na, Pe, Cp, Ch, Sxt
01-066 CTX-M-14 B2 O4 10 S, Te, Mi, Sxt
02-008 CTX-M-14 B2e O25b 8 Na, Pe, Cp
05-029 CTX-M-14 A 2 Te, Na, Pe, Cp, Sxt
08-024 CTX-M-14 A 8 S, Te, Mi, Sxt
12-028 CTX-M-14 A 2 K, G, T, N, A, Te, Mi, Na, Pe, Cp, Ch, Sxt
11-078 CTX-M-14 D O16 10 Te, Mi, Na, Pe, Cp, Sxt
02-018 CTX-M-1 A O78 5 S, K, Te, Mi, Na, Pe, Cp, Ch, Sxt
12-176 CTX-M-1 A 2 Te, Mi, Sxt
05-058 CTX-M-15 + OXA-1 A 1 K, G, T, N, Te, Mi, Na, Pe, Cp, Ch, Sxt
11-080 CTX-M-15 + OXA-1 A 0 K, G, T, N, Te, Mi, Na, Pe, Cp, Ch, Sxt
11-104 CTX-M-15 + OXA-1 A 2 K, G, T, N, Te, Mi, Na, Pe, Cp, Sxt
05-032 CTX-M-15 + OXA-1 B2e O25b 8 K, G, T, N, Mi, Na, Pe, Cp
06-024 CTX-M-15 + OXA-1 B2e O25b 5 S, K, T, N, A, Te, Mi, Na, Pe, Cp, Sxt
13-011 CTX-M-15 + OXA-1 B2e O25b 7 K, G, T, N, Na, Pe, Cp, Sxt
13-027 CTX-M-15 B2e O25b 4 Mi, Na, Pe, Cp
13-038 CTX-M-15 B2e O25b 8 Mi, Na, Pe, Cp, Ch
11-005 CTX-M-15 A 3 K, G, T, N, Te, Mi, Na, Pe, Cp, Sxt
06-008 TEM-52 A 3 S, K, Te, Mi, Na, Pe, Cp, Ch, Sxt
10-020 CMY-2 A 3 Te, Mi, Na, Pe, Cp, Ch, Sxt
04-004 AmpC A 5 S, Te, Mi, Sxt
06-021 AmpC A O21 4 S, Te, Mi, Ch, Sxt
08-092 AmpC A 7 S, Te, Mi, Sxt
12-140 AmpC A 6 S, K, Te, Mi, Sxt
13-030 AmpC A 9 S, K, Te, Mi, Ch, Sxt
12-133 AmpC B1 0
12-169 AmpC B2 O7 11 S, Te, Mi, Sxt
05-008 AmpC B2 O6 15 Na
08-152 AmpC + CMY-2 A 5 S, Te, Mi, Na, Pe, Cp, Sxt
12-003 AmpC + CMY-2 A 1 S, Te, Mi, Na, Pe, Cp, Ch, Sxt
12-015 AmpC + CMY-2 B1 4 K, G, T, Te, Mi, Na, Pe, Cp, Sxt
12-052 AmpC A 8 S, K, Te, Mi, Na, Sxt
06-006 AmpC A 6 Mi, Na, Pe, Cp, Ch
06-062 AmpC D 5 Te, Mi, Na, Pe, Cp, Sxt
07-107 AmpC A 6 Mi, Na, Pe, Cp
05-063 AmpC + CMY-2 A 5 S, K, Te, Mi, Na, Pe, Cp, Sxt
08-121 AmpC A 5 S, K, Te, Mi, Na, Pe, Ch, Cp, Sxt
02-033 OXA-1 D 5 Te, Na, Pe, Cp, Ch
07-102 OXA-1 B2 16 S, K, Te, Mi, Ch
08-110 OXA-1 A 8 S, K, Te, Mi, Na, Pe, Cp, Ch, Sxt
11-153 OXA-1 A 4 S, K, G, T, Te, Mi, Na, Pe, Cp, Ch, Sxt
aDetermined as in [11].
bDetermined as in [13], among a pool of 25 O-types (see Materials and Methods and Table S1). The absence of results indicates that the isolates do not belong to any of the
O-types searched for.
cVF, virulence factor.
dS, streptomycin; K, kanamycin; G, gentamicin; T, tobramycin; N, netilmicin; A, amikacin; Te, tetracycline; Mi, minocycline; Na, nalidixic acid; Pe, peﬂoxacin; Cp, ciproﬂoxacin;
Ch, chloramphenicol; Sxt, trimethoprim–sulphonamides.
eStrains belonging to the O25b:H4-ST131 clone.
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appropriate antimicrobial therapy to cure these severe infec-
tions [33].
Phylogroup A was the most common (61%) among the
3GC-R strains, and less common among the 3GC-S strains
(p <0.0001), where phylogroups B2 or D are predominant
(Table 3). This result agrees with several observations show-
ing that resistant strains of E. coli belong to phylogroups that
are usually considered to have low virulence [7,34], i.e. A,
B1 and D [35]. Indeed, 3GC-R strains carried signiﬁcantly
fewer virulence factors than 3GC-S strains (p <0.0001).
These results also conﬁrm that the trade-off between resis-
tance to ﬂuoroquinolones and virulence [7,36] is also found
in E. coli strains isolated from bacteraemias. Finally, with the
exception of the strains belonging to the ST131 clone, only
six strains were O-typed (Table 1), indicating that the 3GC-
R strains of COLIBAFI do not express the O-types usually
described in E. coli strains involved in extra-intestinal infec-
tions [13].
Prior use of antibiotics and underlying chronic disease
\are risk factors for development of 3GC-resistant E. coli
bacteraemia
The majority of the patients developed a community-
acquired infection. Several factors were found to be different
Strain
number
AmpC + CMY2 12-015
AmpC  12-169
Resistance
type
Phylogenetic
group
CTX-M-14               B1        08-024
AmpC   08-121
AmpC  06-062
AmpC        12-140
AmpC                      A      10-020
CTX-M-15               B2        05-032
CTX-M-15               B2        13-038
CTX-M-14             A          11-078
CTX-M-15               B2        13-027
CTX-M-15               B2        13-011
CTX-M-15               B2        06-024
CTX-M-14               B2        02-008
CTX-M-15               A          05-058
CTX-M-15               A          11-005
CTX-M-15               A          11-104
CTX-M-9                 B2        02-007
TEM-52                   A          06-008
AmpC       12-133
AmpC A          04-004
AmpC A          08-092
AmpC  A          07-107
AmpC A          06-006
AmpC + CMY2
AmpC + CMY2
CTX-M-14               A          05-029
AmpC A          12-052
AmpC A          13-030
CTX-M-1              A          02-018
CTX-M-1               A          12-076
CTX-M-14             B2        01-066
CTX-M-14             A          12-028
AmpC       05-008
CTX-M-15               A          11-080
AmpC + CMY2
AmpC
B1
B2
A
D1
A
B1
A 05-063
A 12-003
B2
A 08-152
A    06-021
O25: H4-ST131
clone 
% of Similarity 
40 50 60 70 80 90 100
FIG. 1. Dendrogram showing the estimated genetic relationships among the Escherichia coli strains harbouring an extended-spectrum b-lactam-
ase or AmpC phenotype. The dendrogram was generated by applying the UPGMA algorithm to XbaI patterns.
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between the 3GC-S and the 3GCR groups (Table 4). The
following risk factors were identiﬁed by multivariate analysis:
underlying chronic disease (OR 2.20 (95% CI 1.15–4.20),
p 0.0176), prior use of antibiotics (OR 2.58 (95% CI 1.30–
5.13), p 0.0069) and an unidentiﬁed or non-standard portal
of entry (OR 2.04 (95% CI 1.06–3.93), p 0.0331).
Bacteraemias with 3GC-R isolates were more frequently
associated with death than bacteraemias with 3GC-S isolates
(p 0.0024) (Table 4). The full study of risk factors associated
with death in the COLIBAFI study will be presented else-
where (A. Lefort, X. Panhard, O. Clermont, P. L. Woerther,
C. Branger, F. Mentre´, B. Fantin, M. Wolff, E. Denamur and
the COLIBAFI group; personal communication).
Within the 3GC-R group, male sex was predominant in
the ESBL group, which is consistent with previous published
data [33]. Immunosuppression (p 0.036) and prior antibiotic
treatment (p 0.0041) seemed to be more important risk
factors for developing an infection with ESBL-producing
E. coli than for developing an infection with an AmpC-over-
producing strains. Bacteraemia was no more lethal in the
ESBL group than in the AmpC group (Table 4).
In conclusion the COLIBAFI study showed that, in France
in 2005, 3.8% of E. coli strains responsible for bacteraemia
had decreased susceptibility to 3GCs. This study relied on a
prospective and multicentre approach, making it well repre-
sentative of French epidemiology. Moreover, the statistical
comparison between the 3GC-R group and the 3GC-S
group seems to be the best study design with which to
investigate factors associated with antimicrobial resistance
[20]. However, the low number of 3GC-R strains may have
led to an underestimation of the presence of confounding
bias. ESBL-producing strains and AmpC producers were
equally represented. Resistance was plasmid-mediated in
68.3% of the cases, representing a potentially epidemic
TABLE 3. Statistical comparison of
microbiological data of Escherichia
coli strains of the COLIBAFI study
Variable
3GC-S vs. 3GC-R strains
ESBL-producing vs.
AmpC-producing strains
3GC-S
(n = 1040)
3GC-R
(n = 41) p1
ESBL
(n = 19)
AmpC
(n = 18) p2
Antimicrobial resistance, n (%)
Ciproﬂoxacin 101 (9.7) 28 (68.3) <0.0001 16 (84.2) 9 (50) 0.04
Gentamicin 39 (3.8) 10 (24.4) <0.0001 8 (42.1) 1 (5.6) 0.02
Amikacin 11 (1) 3 (7.32) 0.01 3 (15.8) 0 (0) 0.23
Co-trimoxazole 291 (28) 31 (75.6) <0.0001 15 (79) 14 (77.8) 1
Phylogenetic group, n (%)
A 221 (21.3) 25 (61) <0.0001 10 (52.6) 13 (72.2) 0.08
B1 46 (4.4) 2 (4.9) 0 2 (11.1)
B2 549 (52.8) 11 (26.8) 8 (42.1) 2 (11.1)
D 224 (21.5) 3 (7.3) 1 (5.3) 1 (5.6)
VF score, mean ± SD 8.2 ± 4.3 5.6 ± 3.6 <0.0001 4.9 ± 3.1 5.8 ± 3.5 0.43
3GC-S, susceptible to third-generation cephalosporins (3GCs); 3GC-R, resistant to 3GCs; ESBL, extended-spectrum
b-lactamase; p1, p-value for the comparison between 3GC-S and 3GC-R strains; p2, p-value for the comparison
between ESBL-producing and AmpC-producing strains; VF score, virulence factor score; SD, standard deviation.
TABLE 4. Clinical characteristics
of patients presenting with an
Eschrichia coli bacteraemia
Variable
Patients infected with:
3GC-S
isolate
(n = 1012)
3GC-R
isolate
(n = 39) p1
ESBL-producing
isolate (n = 19)
AmpC-producing
isolate (n = 16) p2
Age (years), mean ± SD 66.8 ± 17.6 71.2 ± 13.2 0.20 69.8 ± 14.0 74.8 ± 12.9 0.21
Male sex 424 (41.9) 23 (59.0) 0.046 13 (68.4) 8 (50.0) 0.32
Underlying chronic disease 311 (30.7) 19 (48.7) 0.022 10 (52.6) 6 (37.5) 0.50
Immunosuppression 380 (37.6) 17 (43.6) 0.50 11 (57.9) 3 (18.8) 0.036
Prior use of antibiotic 162 (16.0) 14 (35.9) 0.0032 10 (52.6) 1 (6.3) 0.0041
Origin of infection
Community-acquired 819 (80.9) 30 (76.9) 0.54 15 (79.0) 13 (81.3) 1
Nosocomial 193 (19.1) 9 (23.1) 4 (21.0) 3 (18.7)
Portal of entry
Urinary tract 583 (57.6) 15 (38.5) 0.021 5 (26.3) 9 (56.3) 0.09
Intra-abdominal 133 (13.1) 5 (12.8) 1.00 3 (15.8) 2 (12.5) 1
Others or unknown 303 (29.9) 19 (48.7) 0.020 11 (57.9) 5 (31.3) 0.18
Death 124 (12.25) 12 (30.77) 0.0024 5 (26.3) 4 (25.0) 1
Data are no. and percentages of patients, unless otherwise indicated.
3GC-S, susceptible to third-generation cephalosporins (3GCs); 3GC-R, resistant to 3GCs; ESBL, extended-spectrum
b-lactamase; p1, p-value for the comparison between the 3GC-S group and the 3GC-R group; p2, p-value for the
comparison between ESBL-producing and AmpC-producing strains; SD, standard deviation.
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threat. These 3GC-R strains, mostly community-acquired,
were signiﬁcantly more frequent in patients with underlying
chronic disease and were associated with a more severe
outcome. Prior use of antibiotics and immunosuppression
are greater risk factors for infection by ESBL-producing
strains than for infection by AmpC overproducers. Adequate
antimicrobial therapy of ESBL-producing strains relies on
carbapenems, whereas cefepime could usually be used to
treat infections with AmpC producers. The recent revision
of the MIC breakpoints for cephalosporins by the European
Committee on Antimicrobial Susceptibility Testing (EUCAST:
http://www.escmid.org) and the CA-SFM will have an impact
on the susceptibility categorization of cefepime. The initial
breakpoint was lowered from 4 mg/L to 1 mg/L, which
might decrease the number of strains categorized as suscep-
tible among the AmpC-producing strains. This could lead to
an increase in the use of carbapenems, with the threat of
contributing to the emergence and spread of carbapenem-
resistant E. coli [37].
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